Lataa...
Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
Immunotherapy has considerably increased the number of anticancer agents in many tumor types including metastatic colorectal cancer (mCRC). Anti-PD-1 (programmed death 1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI) have been shown to benefit the mCRC p...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7225960/ https://ncbi.nlm.nih.gov/pubmed/32268531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040889 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|